Related Experiment Video
Updated: Jan 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer
Bette S Pollard1, Mark A Suckow2, William R Wolter2
1Silver Pharmaceuticals, Rockville, MD, United States.
Abstract:
Castration Resistant Prostate Cancer (CRPC) is thought to be driven by a collaborative mechanism between TNFα/NFκB and TGFβ signaling, leading to inflammation, Epithelial-to-Mesenchymal-Transition (EMT), and metastasis. Initially, TGFβ is a tumor suppressor, but in advanced metastatic disease it switches to being a tumor promoter. TGFBR2 may play a critical role in this collaboration, as its expression is driven by NFκB and it is the primary receptor for TGFβ. We have previously reported that the cardenolide drug digitoxin blocks TNFα/NFκB-driven proinflammatory signaling. We therefore hypothesized that digitoxin might break the collaborative process between NFκB and TGFβ by also inhibiting expression of TGFBR2. We therefore tested whether TGFβ-driven EMT and resulting metastases would be suppressed. Here we show, in vitro, that digitoxin inhibits NFκB-driven TGFBR2 expression, as well as Vimentin, while elevating E-cadherin expression. Digitoxin also significantly reduces HSPB1 mRNA and the HSPB1/RBFOX2 mRNA ratio in PC3 cells. In vivo, in a syngeneic, immune competent rat model of metastatic CRPC, we show that digitoxin also suppresses Tgfbr2 expression, as well as expression of other genes classically driven by NFκB, and of multiple EMT genes associated with metastasis. Concurrently, digitoxin suppresses tumor growth and metastasis in these animals, and prolongs survival. Gross tumor recurrence following tumor resection also appears prevented in ca 30% of cases. While the existence of a collaboration between NFκB and TGFβ to drive EMT and metastasis has previously been appreciated, we show here, for the first time, that chronic, low concentrations of digitoxin are able to block CRPC tumor progression, EMT and the ensuing metastatic disease.
Insights
Digitoxin blocks the collaboration between TNFα/NFκB and TGFβ signaling pathways, inhibiting tumor progression and metastasis in Castration Resistant Prostate Cancer (CRPC). This drug suppresses key genes involved in inflammation and epithelial-to-mesenchymal transition (EMT).
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Castration-Resistant Prostate Cancer (CRPC) progression involves a collaboration between TNFα/NFκB and TGFβ signaling, driving inflammation, Epithelial-to-Mesenchymal-Transition (EMT), and metastasis.
- TGFβ signaling shifts from tumor suppression to promotion in advanced metastatic disease, with TGFBR2 potentially mediating the collaboration due to NFκB-driven expression.
- Previous work showed digitoxin inhibits TNFα/NFκB-driven proinflammatory signaling.
Purpose of the Study:
- To test the hypothesis that digitoxin inhibits the collaborative process between NFκB and TGFβ signaling by inhibiting TGFBR2 expression.
- To evaluate the efficacy of digitoxin in suppressing TGFβ-driven EMT and subsequent metastases in CRPC.
Main Methods:
- In vitro experiments assessed digitoxin's effects on NFκB-driven TGFBR2 expression, Vimentin, E-cadherin, HSPB1 mRNA, and the HSPB1/RBFOX2 mRNA ratio in PC3 cells.
- In vivo studies utilized a syngeneic, immune-competent rat model of metastatic CRPC to evaluate digitoxin's impact on Tgfbr2, NFκB-driven genes, and EMT genes.
- Tumor growth, metastasis, recurrence, and survival were monitored in the animal model.
Main Results:
- In vitro, digitoxin inhibited NFκB-driven TGFBR2 expression, Vimentin, HSPB1 mRNA, and the HSPB1/RBFOX2 mRNA ratio, while increasing E-cadherin.
- In vivo, digitoxin suppressed Tgfbr2, NFκB-driven genes, and EMT-associated metastasis genes, leading to reduced tumor growth and metastasis.
- Digitoxin treatment prolonged survival and appeared to prevent gross tumor recurrence in approximately 30% of cases.
Conclusions:
- Digitoxin effectively blocks the collaborative signaling between NFκB and TGFβ that drives CRPC progression, EMT, and metastasis.
- Chronic, low-dose digitoxin administration demonstrates significant potential in inhibiting CRPC tumor progression and metastatic disease.
- This study provides the first evidence that digitoxin can block CRPC progression and associated EMT and metastasis.
Related Concept Videos
Treatment Resistant Cancers
Phase Transitions
Feedback Inhibition
Properties of Transition Metals
Cooperative Allosteric Transitions
Phase Transitions: Vaporization and Condensation

